Stockscreener 앱 받기
28.70
1.98%
-0.58
전일 마감가:
$29.28
열려 있는:
$29.42
하루 거래량:
1.12M
Relative Volume:
1.09
시가총액:
$1.64B
수익:
$199.89M
순이익/손실:
$52.48M
주가수익비율:
33.76
EPS:
0.85
순현금흐름:
$61.15M
1주 성능:
-12.63%
1개월 성능:
-14.61%
6개월 성능:
+141.18%
1년 성능:
+203.38%
1일 변동 폭
$28.52
$30.13
1주일 범위
$25.21
$31.70
52주 변동 폭
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
28.70 | 1.67B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics (STOK) Price Target Increased by 10.42% to 36.46 - Nasdaq
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Phase III update Stokes hope; Dravet game-change Encoded? - BioWorld MedTech
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall - marketscreener.com
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline By Investing.com - Investing.com Nigeria
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline - Investing.com
Wedbush Raises Price Target for Stoke Therapeutics (STOK) to $36 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush - MarketBeat
8 Analysts Have This To Say About Stoke Therapeutics - Benzinga
Stoke Therapeutics (NASDAQ: STOK) sees cash runway into 2028 operations - Stock Titan
Some Analysts Just Cut Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Estimates - 富途牛牛
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - The AI Journal
Stoke Therapeutics Targets Mid-2027 Phase 3 Readout To Support FDA Filing Of Zorevunersen - Nasdaq
Biogen (BIIB) Advances with Zorevunersen Development Program - GuruFocus
Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen - TradingView — Track All Markets
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Strong Buy Ratings Amid Impressive Revenue Growth and Promising Pipeline - DirectorsTalk Interviews
Why hedge funds are buying Stoke Therapeutics Inc. stockGrip and Outsole Review & size guide reminders to avoid returns - ulpravda.ru
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Stoke Therapeutics Inc. stock a buy in volatile marketsQuarterly Market Review & Fast Gaining Stock Strategy Reports - Улправда
Fed Meeting: Is Stoke Therapeutics Inc. stock vulnerable to regulatory risksMarket Sentiment Report & Weekly High Return Stock Opportunities - ulpravda.ru
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - Улправда
Breakouts Watch: Will Stoke Therapeutics Inc. stock gain from strong economyQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - ulpravda.ru
EBIT per share of Stoke Therapeutics, Inc. – MUN:0GT - TradingView — Track All Markets
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Tangible book value per share of Stoke Therapeutics, Inc. – DUS:0GT - TradingView — Track All Markets
Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock By Investing.com - Investing.com Canada
Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat
Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus
Chardan Capital Markets assumes coverage on Stoke Therapeutics stock with Buy rating - Investing.com Canada
Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation - MSN
Stoke Therapeutics (STU:0GT) EV-to-OCF : 25.98 (As of Dec. 23, 2025) - GuruFocus
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus
Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS
Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat
Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):